Tim Shannon

General Partner / East Coast

Since 2009

Tim pairs his operating experience and medical background to create value for companies from the earliest stage through FDA approval. Prior to becoming an investor, Tim was president and chief executive officer of CuraGen, a publicly traded biopharmaceutical company focused on oncology. He began his career as a pulmonary and critical care physician. Tim earned his medical degree from the University of Connecticut and has a B.A. in chemistry from Amherst College.

Tim in 5

Travel: Did it early in life - I like New England now!

Sport: UCONN Basketball

Family: Large

Accomplishments: Raising 5 children (a work in progress)

Bucket List: Completing 10th marathon



  • Arvinas
    IPO (ARVN)
  • IDEAYA Biosciences
    IPO (IDYA)
  • Vivace Therapeutics
  • Previous

    • Civitas Therapeutics
      Acquired by Acorda Therapeutics
    • CytomX
    • NextCure
      IPO (NXTC)
    • Novira Therapeutics
      Acquired by Johnson & Johnson
    • Rallybio
      Nasdaq (RLYB)


    Endpoints News: Pfizer bets $1B cash on the original protein degraders as technology nears prime time

    Fierce Biotech: Biotech Pfizer funnels $1B into protein degrader Arvinas, with more in biobucks on the table

    Fierce Biotech: Rallybio hires Tuch from BMO to lead corporate development

    Fierce Biotech: Ideaya, Spelman College team up to provide young African American women a stepping stone to biotech careers

    Endpoints News: Vivace Therapeutics scores $30M Series C to take oncology candidate for 'Hippo' pathway to human trial next year

    Fierce Biotech: Vivace snares $30M to push Hippo-targeting drugs into the clinic

    FierceBiotech: Arvinas eyes a busy 2021 as protein degraders gather steam in breast, prostate cancers

    Endpoints News: Billions on the table, GSK’s Hal Barron antes $120M cash to partner with Ideaya

    Fierce Biotech: GlaxoSmithKline pens $120M upfront synthetic lethality cancer pact with Fierce 15 winner Ideaya

    MedCity News: GSK pumps $120M into partnership with Ideaya in oncology precision medicine play

    BioCentury: With Ideaya deal, GSK bulks up synthetic lethality side of oncology business

    FierceBiotech: Rallybio scores $145M, unveils lead rare disease program

    FierceBiotech: Arvinas unveils first-in-human data for novel protein degrader in prostate cancer

    BioCentury: Beyond PROTACs and the proteasome - broadening the TAC toolbox

    Wired: These protein picker-uppers keep your cells clean and healthy

    Endpoints News: Bayer enlists Arvinas on two-pronged protein degradation effort, foraying into agtech

    Tim Shannon in BioCentury: Making orphan drug prices work for society

    Endpoints News: Four biotechs, including NextCure, haul in $303M+ from a fresh burst of IPOs

    Business Insider: Scientists are working on cancer treatments that attack the disease's 'Holy Grail"

    Endpoints News: Backed with $180M-plus in cash, I/O trailblazer Lieping Chen spotlights NextCure's preclinical work on next-gen antibody

    Nature: Protein-slaying drugs could be the next blockbuster therapies

    Nature Reviews: First targeted protein degrader, developed by Arvinas, hits the clinic

    Nasdaq: Cancer biotech Arvinas prices upsized IPO at $16

    Tim Shannon: More hope for cystic fibrosis treatment, and still more to do

    Scientific American: New thalidomide-like therapy hijacks cells’ trash-disposal system

    Fierce Biotech: Mackay’s Rallybio rare disease startup raises $37M in first funding round

    IDEAYA & the Next Frontier in Synthetic Lethality

    FierceBiotech: GV, Roche help Ideaya to $94M crossover round, setting stage for synthetic lethality, I-O trials

    FierceBiotech: Arvinas in $830M-plus Pfizer biobucks deal

    BioCentury Innovations: How Vivace turns the YAP pathway off or on to treat cancer

    Endpoints News: Genentech inks $650M deal with protein degradation pioneer Arvinas

    Fierce Biotech: Canaan unveils $800 million fund for fresh wave of biotech bets

    Fierce Biotech: Vivace uncloaks with $40M, U.S./China backing for cancer trials

    Endpoints: Canaan reels in a jumbo $800 million with a big focus on a new wave of startups

    STAT: Forget the science. These investors think they can pick biotech winners by algorithm

    Tim Shannon: Durable bonds and the birth of Vivace Therapeutics

    Tim in 5

    Travel: Did it early in life - I like New England now!

    Sport: UCONN Basketball

    Family: Large

    Accomplishments: Raising 5 children (a work in progress)

    Bucket List: Completing 10th marathon